Top

Published in:

01-11-2018 | Review Article

Advances in understanding the genetic basis of diabetic kidney disease

Authors: Man Li, Marcus G. Pezzolesi

Published in: Acta Diabetologica | Issue 11/2018

Abstract

Diabetic kidney disease (DKD) is a devastating complication of Type 1 and Type 2 diabetes and leads to increased morbidity and mortality. Earlier work in families has provided strong evidence that heredity is a major determinant of DKD. Previous linkage analyses and candidate gene studies have identified potential DKD genes; however, such approaches have largely been unsuccessful. Genome-wide association studies (GWAS) have made significant contribution in identifying SNPs associated with common complex diseases. Thanks to advanced technology, new analytical approaches, and international research collaborations, many DKD GWASs have reported unique genes, highlighted novel biological pathways and suggested new disease mechanisms. This review summarizes the current state of GWAS technology; findings from GWASs of DKD and its related traits conducted over the past 15 years and discuss the future of this field.

Krolewski ASWJ (1997) Clinical features and epidemiology of diabetic nephropathy. In: Pickup JCWG (ed) Textbook of diabetes, vol 2, 2nd edn. Blackwell Scientific Publications, Oxford, pp 53.51–53.13

Parving HHMM, Ritz E (2004) Diabetic nephropathy. In: BM B (ed) Brenner and Rector’s the kidney, 7th edn. Elsevier, Philadelphia, pp 1777–1818

Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH (2005) Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int 67(5):1684–1691CrossRefPubMed

Fogarty DG, Rich SS, Hanna L, Warram JH, Krolewski AS (2000) Urinary albumin excretion in families with type 2 diabetes is heritable and genetically correlated to blood pressure. Kidney Int 57(1):250–257CrossRefPubMed

Forsblom CM, Kanninen T, Lehtovirta M, Saloranta C, Groop LC (1999) Heritability of albumin excretion rate in families of patients with Type II diabetes. Diabetologia 42(11):1359–1366CrossRefPubMed

Hunter DJ, Lange M, Snieder H, MacGregor AJ, Swaminathan R, Thakker RV, Spector TD (2002) Genetic contribution to renal function and electrolyte balance: a twin study. Clin Sci (Lond) 103(3):259–265CrossRef

Krolewski AS, Poznik GD, Placha G, Canani L, Dunn J, Walker W, Smiles A et al (2006) A genome-wide linkage scan for genes controlling variation in urinary albumin excretion in type II diabetes. Kidney Int 69(1):129–136CrossRefPubMed

Langefeld CD, Beck SR, Bowden DW, Rich SS, Wagenknecht LE, Freedman BI (2004) Heritability of GFR and albuminuria in Caucasians with type 2 diabetes mellitus. Am J Kidney Dis 43(5):796–800CrossRefPubMed

Hipkiss AR, Preston JE, Himsworth DT, Worthington VC, Keown M, Michaelis J, Lawrence J et al (1998) Pluripotent protective effects of carnosine, a naturally occurring dipeptide. Ann N Y Acad Sci 854:37–53CrossRefPubMed

10.

Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K et al (2001) Initial sequencing and analysis of the human genome. Nature 409(6822):860–921. https://doi.org/10.1038/35057062 CrossRefPubMed

11.

International HapMap C (2005) A haplotype map of the human genome. Nature 437(7063):1299–1320. https://doi.org/10.1038/nature04226 CrossRef

12.

Reich DE, Lander ES (2001) On the allelic spectrum of human disease. Trends Genet 17(9):502–510CrossRefPubMed

13.

Pezzolesi MG, Skupien J, Mychaleckyj JC, Warram JH, Krolewski AS (2010) Insights to the genetics of diabetic nephropathy through a genome-wide association study of the GoKinD collection. Semin Nephrol 30(2):126–140. https://doi.org/10.1016/j.semnephrol.2010.01.004 CrossRefPubMedPubMedCentral

14.

Wang WY, Barratt BJ, Clayton DG, Todd JA (2005) Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 6(2):109–118. https://doi.org/10.1038/nrg1522 CrossRefPubMed

15.

Grayson BL, Smith ME, Thomas JW, Wang L, Dexheimer P, Jeffrey J, Fain PR et al (2010) Genome-wide analysis of copy number variation in type 1 diabetes. PLoS One 5(11):e15393. https://doi.org/10.1371/journal.pone.0015393 CrossRefPubMedPubMedCentral

16.

Wheeler E, Huang N, Bochukova EG, Keogh JM, Lindsay S, Garg S, Henning E et al (2013) Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity. Nat Genet 45(5):513–517. https://doi.org/10.1038/ng.2607 CrossRefPubMedPubMedCentral

17.

Marchini J, Howie B (2010) Genotype imputation for genome-wide association studies. Nat Rev Genet 11(7):499–511. https://doi.org/10.1038/nrg2796 CrossRefPubMed

18.

Browning SR, Browning BL (2007) Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am J Human Genet 81(5):1084–1097. https://doi.org/10.1086/521987 CrossRef

19.

Marchini J, Howie B, Myers S, McVean G, Donnelly P (2007) A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 39(7):906–913. https://doi.org/10.1038/ng2088 CrossRefPubMed

20.

Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR (2010) MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 34(8):816–834. https://doi.org/10.1002/gepi.20533 CrossRefPubMedPubMedCentral

21.

Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL et al (2015) A global reference for human genetic variation. Nature 526(7571):68–74. https://doi.org/10.1038/nature15393 CrossRefPubMed

22.

Najafian B, Mauer M (2012) Morphologic features of declining renal function in type 1 diabetes. Semin Nephrol 32(5):415–422. https://doi.org/10.1016/j.semnephrol.2012.07.003 CrossRefPubMedPubMedCentral

23.

Krolewski AS, Bonventre JV (2012) High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline. Semin Nephrol 32(5):407–414. https://doi.org/10.1016/j.semnephrol.2012.07.002 CrossRefPubMedPubMedCentral

24.

Finne P, Reunanen A, Stenman S, Groop PH, Gronhagen-Riska C (2005) Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 294(14):1782–1787. https://doi.org/10.1001/jama.294.14.1782 CrossRefPubMed

25.

Harjutsalo V, Maric C, Forsblom C, Thorn L, Waden J, Groop PH (2011) Sex-related differences in the long-term risk of microvascular complications by age at onset of type 1 diabetes. Diabetologia 54(8):1992–1999. https://doi.org/10.1007/s00125-011-2144-2 CrossRefPubMed

26.

Sandholm N, Salem RM, McKnight AJ, Brennan EP, Forsblom C, Isakova T, McKay GJ et al (2012) New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet 8(9):e1002921. https://doi.org/10.1371/journal.pgen.1002921 CrossRefPubMedPubMedCentral

27.

Teumer A, Tin A, Sorice R, Gorski M, Yeo NC, Chu AY, Li M et al (2016) Genome-wide association studies identify genetic loci associated with albuminuria in diabetes. Diabetes 65(3):803–817. https://doi.org/10.2337/db15-1313 CrossRefPubMed

28.

van Zuydam NR, Ahlqvist E, Sandholm N, Deshmukh H, Rayner NW, Abdalla M, Ladenvall C et al (2018) A genome-wide association study of diabetic kidney disease in subjects with Type 2 diabetes. Diabetes. https://doi.org/10.2337/db17-0914 CrossRefPubMedPubMedCentral

29.

Sandholm N, Van Zuydam N, Ahlqvist E, Juliusdottir T, Deshmukh HA, Rayner NW, Di Camillo B et al (2017) The genetic landscape of renal complications in Type 1 diabetes. J Am Soc Nephrol 28(2):557–574. https://doi.org/10.1681/ASN.2016020231 CrossRefPubMed

30.

Iyengar SK, Sedor JR, Freedman BI, Kao WH, Kretzler M, Keller BJ, Abboud HE et al (2015) Genome-wide association and trans-ethnic meta-analysis for advanced diabetic kidney disease: family investigation of nephropathy and diabetes (FIND). PLoS Genet 11(8):e1005352. https://doi.org/10.1371/journal.pgen.1005352 CrossRefPubMedPubMedCentral

31.

Pezzolesi MG, Poznik GD, Mychaleckyj JC, Paterson AD, Barati MT, Klein JB, Ng DP et al (2009) Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes 58(6):1403–1410. https://doi.org/10.2337/db08-1514 CrossRefPubMedPubMedCentral

32.

Shimazaki A, Kawamura Y, Kanazawa A, Sekine A, Saito S, Tsunoda T, Koya D et al (2005) Genetic variations in the gene encoding ELMO1 are associated with susceptibility to diabetic nephropathy. Diabetes 54(4):1171–1178CrossRefPubMed

33.

Germain M, Pezzolesi MG, Sandholm N, McKnight AJ, Susztak K, Lajer M, Forsblom C et al (2015) SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes. Diabetologia 58(3):543–548. https://doi.org/10.1007/s00125-014-3459-6 CrossRefPubMed

34.

Tanaka N, Babazono T, Saito S, Sekine A, Tsunoda T, Haneda M, Tanaka Y et al (2003) Association of solute carrier family 12 (sodium/chloride) member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. Diabetes 52(11):2848–2853CrossRefPubMed

35.

Mueller PW, Rogus JJ, Cleary PA, Zhao Y, Smiles AM, Steffes MW, Bucksa J et al (2006) Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol 17(7):1782–1790. https://doi.org/10.1681/ASN.2005080822 CrossRefPubMed

36.

Pezzolesi MG, Poznik GD, Skupien J, Smiles AM, Mychaleckyj JC, Rich SS, Warram JH et al (2011) An intergenic region on chromosome 13q33.3 is associated with the susceptibility to kidney disease in type 1 and 2 diabetes. Kidney Int 80(1):105–111. https://doi.org/10.1038/ki.2011.64 CrossRefPubMedPubMedCentral

37.

Palmer ND, Ng MC, Hicks PJ, Mudgal P, Langefeld CD, Freedman BI, Bowden DW (2014) Evaluation of candidate nephropathy susceptibility genes in a genome-wide association study of African American diabetic kidney disease. PloS One 9(2):e88273. https://doi.org/10.1371/journal.pone.0088273 CrossRefPubMedPubMedCentral

38.

Maeda S, Araki S, Babazono T, Toyoda M, Umezono T, Kawai K, Imanishi M et al (2010) Replication study for the association between four Loci identified by a genome-wide association study on European American subjects with type 1 diabetes and susceptibility to diabetic nephropathy in Japanese subjects with type 2 diabetes. Diabetes 59(8):2075–2079. https://doi.org/10.2337/db10-0067 CrossRefPubMedPubMedCentral

39.

Sandholm N, McKnight AJ, Salem RM, Brennan EP, Forsblom C, Harjutsalo V, Makinen VP et al (2013) Chromosome 2q31.1 associates with ESRD in women with type 1 diabetes. J Am Soc Nephrol 24(10):1537–1543. https://doi.org/10.1681/ASN.2012111122 CrossRefPubMedPubMedCentral

40.

Sandholm N, Forsblom C, Makinen VP, McKnight AJ, Osterholm AM, He B, Harjutsalo V et al (2014) Genome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes. Diabetologia 57(6):1143–1153. https://doi.org/10.1007/s00125-014-3202-3 CrossRefPubMed

41.

Kao WH, Klag MJ, Meoni LA, Reich D, Berthier-Schaad Y, Li M, Coresh J et al (2008) MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 40(10):1185–1192CrossRefPubMed

42.

Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, Bowden DW, Oleksyk T et al (2008) MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 40(10):1175–1184CrossRefPubMedPubMedCentral

43.

Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, Freedman BI, Bowden DW et al (2010) Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329(5993):841–845. https://doi.org/10.1126/science.1193032 CrossRefPubMedPubMedCentral

44.

Pattaro C, Teumer A, Gorski M, Chu AY, Li M, Mijatovic V, Garnaas M et al (2016) Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nat Commun 7:10023. https://doi.org/10.1038/ncomms10023 CrossRefPubMedPubMedCentral

45.

Gallagher MD, Chen-Plotkin AS (2018) The post-GWAS era: from association to function. Am J Human Genet 102(5):717–730. https://doi.org/10.1016/j.ajhg.2018.04.002 CrossRef

46.

Shimazaki A, Tanaka Y, Shinosaki T, Ikeda M, Watada H, Hirose T, Kawamori R et al (2006) ELMO1 increases expression of extracellular matrix proteins and inhibits cell adhesion to ECMs. Kidney Int 70(10):1769–1776CrossRefPubMed

47.

Martini S, Nair V, Patel SR, Eichinger F, Nelson RG, Weil EJ, Pezzolesi MG et al (2013) From single nucleotide polymorphism to transcriptional mechanism: a model for FRMD3 in diabetic nephropathy. Diabetes 62(7):2605–2612. https://doi.org/10.2337/db12-1416 CrossRefPubMedPubMedCentral

48.

Gumienny TL, Brugnera E, Tosello-Trampont AC, Kinchen JM, Haney LB, Nishiwaki K, Walk SF et al (2001) CED-12/ELMO, a novel member of the CrkII/Dock180/Rac pathway, is required for phagocytosis and cell migration. Cell 107(1):27–41CrossRefPubMed

49.

Wu HY, Wang Y, Chen M, Zhang X, Wang D, Pan Y, Li L et al (2013) Association of ELMO1 gene polymorphisms with diabetic nephropathy in Chinese population. J Endocrinol Invest 36(5):298–302. https://doi.org/10.3275/8525 CrossRefPubMed

50.

Leak TS, Perlegas PS, Smith SG, Keene KL, Hicks PJ, Langefeld CD, Mychaleckyj JC et al (2009) Variants in intron 13 of the ELMO1 gene are associated with diabetic nephropathy in African Americans. Ann Hum Genet 73(2):152–159CrossRefPubMedPubMedCentral

51.

Hanson RL, Millis MP, Young NJ, Kobes S, Nelson RG, Knowler WC, DiStefano JK (2010) ELMO1 variants and susceptibility to diabetic nephropathy in American Indians. Mol Genet Metab 101(4):383–390CrossRefPubMedPubMedCentral

52.

Pezzolesi MG, Katavetin P, Kure M, Poznik GD, Skupien J, Mychaleckyj JC, Rich SS et al (2009) Confirmation of genetic associations at ELMO1 in the GoKinD collection supports its role as a susceptibility gene in diabetic nephropathy. Diabetes 58(11):2698–2702CrossRefPubMedPubMedCentral

53.

Freedman BI, Langefeld CD, Lu L, Divers J, Comeau ME, Kopp JB, Winkler CA et al (2011) Differential effects of MYH9 and APOL1 risk variants on FRMD3 association with diabetic ESRD in African Americans. PLoS Genet 7(6):e1002150. https://doi.org/10.1371/journal.pgen.1002150 CrossRefPubMedPubMedCentral

54.

Pezzolesi MG, Jeong J, Smiles AM, Skupien J, Mychaleckyj JC, Rich SS, Warram JH et al (2013) Family-based association analysis confirms the role of the chromosome 9q21.32 locus in the susceptibility of diabetic nephropathy. PloS One 8(3):e60301. https://doi.org/10.1371/journal.pone.0060301 CrossRefPubMedPubMedCentral

55.

Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A et al (2017) Genome-wide genetic data on ~ 500,000 UK Biobank participants. BioRxiv. https://doi.org/10.1101/166298 CrossRef

56.

Gaziano JM, Concato J, Brophy M, Fiore L, Pyarajan S, Breeling J, Whitbourne S et al (2016) Million Veteran Program: A mega-biobank to study genetic influences on health and disease. J Clin Epidemiol 70:214–223. https://doi.org/10.1016/j.jclinepi.2015.09.016 CrossRefPubMed

57.

Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS (2003) Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348(23):2285–2293. https://doi.org/10.1056/NEJMoa021835 CrossRefPubMed

58.

Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, Warram JH, Krolewski AS (2007) Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 18(4):1353–1361. https://doi.org/10.1681/asn.2006080872 CrossRefPubMed

59.

Perkins BA, Ficociello LH, Roshan B, Warram JH, Krolewski AS (2010) In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 77(1):57–64. https://doi.org/10.1038/ki.2009.399 CrossRefPubMedPubMedCentral

60.

Skupien J, Warram JH, Smiles AM, Niewczas MA, Gohda T, Pezzolesi MG, Cantarovich D et al (2012) The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int 82(5):589–597. https://doi.org/10.1038/ki.2012.189 CrossRefPubMedPubMedCentral

61.

Krolewski AS (2015) Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care 38(6):954–962. https://doi.org/10.2337/dc15-0184 CrossRefPubMedPubMedCentral

62.

Niewczas MA, Gohda T, Skupien J, Smiles AM, Walker WH, Rosetti F, Cullere X et al (2012) Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes. J Am Soc Nephrol 23(3):507–515. https://doi.org/10.1681/asn.2011060627 CrossRefPubMedPubMedCentral

63.

Gohda T, Niewczas MA, Ficociello LH, Walker WH, Skupien J, Rosetti F, Cullere X et al (2012) Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J Am Soc Nephrol 23(3):516–524. https://doi.org/10.1681/asn.2011060628 CrossRefPubMedPubMedCentral

64.

Pavkov ME, Weil EJ, Fufaa GD, Nelson RG, Lemley KV, Knowler WC, Niewczas MA et al (2016) Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. Kidney Int 89(1):226–234. https://doi.org/10.1038/ki.2015.278 CrossRefPubMedPubMedCentral

65.

Bassi R, Fornoni A, Doria A, Fiorina P (2016) CTLA4-Ig in B7-1-positive diabetic and non-diabetic kidney disease. Diabetologia 59(1):21–29. https://doi.org/10.1007/s00125-015-3766-6 CrossRefPubMed

66.

Baragetti I, El Essawy B, Fiorina P (2017) Targeting immunity in end-stage renal disease. Am J Nephrol 45(4):310–319. https://doi.org/10.1159/000458768 CrossRefPubMed

67.

Dellepiane S, Ben Nasr M, Assi E, Usuelli V, Letizia T, D’Addio F, Zuccotti GV et al (2018) Sodium glucose cotransporters inhibitors in type 1 diabetes. Pharmacol Res 133:1–8. https://doi.org/10.1016/j.phrs.2018.04.018 CrossRefPubMed

68.

The Genotype-Tissue Expression (GTEx) project (2013) Nat Genetics 45(6):580–585. https://doi.org/10.1038/ng.2653 CrossRef

69.

McKnight AJ, McKay GJ, Maxwell AP (2014) Genetic and epigenetic risk factors for diabetic kidney disease. Adv Chron Kidney Dis 21(3):287–296. https://doi.org/10.1053/j.ackd.2014.03.010 CrossRef

70.

Hirayama A, Nakashima E, Sugimoto M, Akiyama S, Sato W, Maruyama S, Matsuo S et al (2012) Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Anal Bioanal Chem 404(10):3101–3109. https://doi.org/10.1007/s00216-012-6412-x CrossRefPubMed

71.

Pena MJ, Lambers Heerspink HJ, Hellemons ME, Friedrich T, Dallmann G, Lajer M, Bakker SJ et al (2014) Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. Diabet Med 31(9):1138–1147. https://doi.org/10.1111/dme.12447 CrossRefPubMed

72.

Stec DF, Wang S, Stothers C, Avance J, Denson D, Harris R, Voziyan P (2015) Alterations of urinary metabolite profile in model diabetic nephropathy. Biochem Biophys Res Commun 456(2):610–614. https://doi.org/10.1016/j.bbrc.2014.12.003 CrossRefPubMed

73.

Zurbig P, Jerums G, Hovind P, Macisaac RJ, Mischak H, Nielsen SE, Panagiotopoulos S et al (2012) Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 61(12):3304–3313. https://doi.org/10.2337/db12-0348 CrossRefPubMedPubMedCentral

74.

Zubiri I, Posada-Ayala M, Sanz-Maroto A, Calvo E, Martin-Lorenzo M, Gonzalez-Calero L, de la Cuesta F et al (2014) Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis. J Proteom 96:92–102. https://doi.org/10.1016/j.jprot.2013.10.037 CrossRef

75.

Caseiro A, Barros A, Ferreira R, Padrao A, Aroso M, Quintaneiro C, Pereira A et al (2014) Pursuing type 1 diabetes mellitus and related complications through urinary proteomics. Transl Res 163(3):188–199. https://doi.org/10.1016/j.trsl.2013.09.005 CrossRefPubMed

Title: Advances in understanding the genetic basis of diabetic kidney disease
Authors: Man Li
Marcus G. Pezzolesi
Publication date: 01-11-2018
Publisher: Springer Milan
Published in: Acta Diabetologica / Issue 11/2018
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-018-1193-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2018

Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study

Measuring visual cortical oxygenation in diabetes using functional near-infrared spectroscopy

Issue focusing: a new topical collection on diabetic nephropathy

The association between cigarette smoking and diabetic nephropathy in Chinese male patients

Glomerular endothelial cells versus podocytes as the cellular target in diabetic nephropathy

Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage